No Data
MIRICOR: ANNUAL REPORT 2023/24
BOC International: Continued prosperity of upstream medical beauty manufacturers opens up space for external expansion.
According to the research reports released by BOC International, the performance of leading medical and aesthetic companies is still maintaining good growth, and the average product price has not shown any price reduction pressure. The constantly enriched product matrix is expected to bring growth in the future.
Miricor Enterprises Reduces Loss in Fiscal Year 2024
Miricor (01827.HK) had an annual revenue of around HKD 490 million, a YoY increase of about 6.7%.
On June 25th, Gleamray announced that its revenue for the fiscal year ended March 31, 2024 was approximately HKD 490 million, an increase of approximately 6.7% year-on-year. For the fiscal year ended March 31, 2024, the company's attributable loss was approximately HKD 12.6 million, a reduction of approximately 38.5% compared to the fiscal year ended March 31, 2023.
Express News | Miricor Enterprises Holdings FY Revenue HKD 494.3 Million
Express News | Miricor Enterprises Holdings FY Net Income HKD -12.6 Million
No Data
No Data